It’s fair to say that the initial results of immunotherapy in neuroendocrine tumors (NETs) have been somewhat disappointing, explained Thorvardur Halfdanarson, MD, associate professor of medicine and consultant in medical oncology, Mayo Clinic.
It’s fair to say that the initial results of immunotherapy in neuroendocrine tumors (NETs) have been somewhat disappointing, explained Thorvardur Halfdanarson, MD, associate professor of medicine and consultant in medical oncology, Mayo Clinic.
Transcript
Is there a future for immunotherapy in neuroendocrine tumors?
I think there is a future for immunotherapy. The problem is that we don’t know who these patients are, who will respond. So, if we look at other cancers like lung cancer where we have a reliable biomarker, such as PD-L1, gastrointestinal malignancies where we have a reliable marker of a response, such as microsatellite instability. We don’t have that in neuroendocrine tumors. They are generally microsatellite stable tumors, and although they may and often express PD-L1, we don’t have good data to suggest that being a good marker. We know from small cell carcinoma of the lung that it probably doesn’t matter a whole lot what your PD-L1 expression is.
So, I think it’s fair to say that the initial results have been somewhat disappointing, but there are still signals and they’re suggesting to me that we need to pursue this as possible therapy. It’s just too hard to say where this will fit in. There are new trials coming down the pike for other malignancies using a combined approach with 2 immunotherapy agents with immunotherapy and cytotoxic therapy, and even immunotherapy with ablative therapies, such as the hepatic embolization or PRRT [peptide receptor radionuclide therapy] is something that I think would be very reasonable to explore.
So, immunotherapy is, I think, is still a target we should go after.
An Overview of Health Care and Pharmaceutical Trends, 2023-2024
April 19th 2024Douglas M. Long, BA, MBA, was featured as the keynote speaker on the closing day of The Academy of Managed Care Pharmacy 2024 annual meeting, with a session dedicated to surveying the health care and pharmaceutical trends of the last year.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Gene and Cell Therapies Hold Potential—but How Can Payers Manage Their Costs?
April 18th 2024Presenters at the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting discussed the current promise and future potential of gene and cell therapies, as well as payer management strategies for these costly treatments.
Read More